An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (MACS1631)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Iron, one of the most common elements in nature and the most abundant transition metal in the body, is readily capable of accepting and donating electrons. This capability makes iron a useful component of various, essential biochemical processes. Despite the essential role of iron, the excess of iron is toxic to the human body. It is critical for the human body to maintain iron balance, since humans have no physiologic mechanism for actively removing iron from the body.
The development of iron overload occurs when iron intake exceeds the body's capacity to safely store the iron in the liver, which is the primary store for iron. Long-term transfusion therapy, a life-giving treatment for patients with intractable chronic anemia is currently the most frequent cause of secondary iron overload.
The mounting evidence regarding the mortality and morbidity due to chronic iron overload in transfusion dependent anaemias has led to the establishment of guidelines that aim the improvement of patient outcomes. Further prospective studies are warranted in order to assess the impact of iron overload in patients with acquired anaemias.
In this study, non-invasive R2- and T2*-MRI techniques will be applied to the liver and the heart, respectively, to complement the primary variable (serum ferritin) assessed in patients with various transfusion-dependent anaemias. The main objective of this study is to assess the prevalence and severity of cardiac and liver siderosis in patients with transfusional siderosis. This study will also aim to establish possible correlations between cardiac and liver iron levels with clinical effects in patients with different transfusion-dependent anaemias. Patients will be eligible for enrollment irrespective of receiving chelation therapy or not (and irrespective of the chelating agent used).
| Condition | Intervention |
|---|---|
|
Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplastic Syndromes, Myelofibrosis, Other Anemia |
Radiation: Single arm MRI test |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) |
- Prevalence and severity of liver and cardiac iron overload in patients with transfusional siderosis (MDS, thalassaemia major and other anaemias). [ Time Frame: 12 months - retrospective ] [ Designated as safety issue: No ]Hepatic and cardiac iron overload in patients with transfusional siderosis (MDS, thalassaemia major and other anaemias) will be measured using MRI to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively). Values will be compared to published thresholds of iron overload to determine severity of transfusion siderosis in the patient population studied.
- Measurement of iron overload due to transfusion therapy comparing chelation-naïve and chelation-treated patient subgroups. [ Time Frame: 12 months - retrospective ] [ Designated as safety issue: No ]The severity of iron overload due to transfusion therapy will be assessed based on chelation status of each patient (i.e. chelation-naïve and chelation-treated patient subgroups).
- Levels of cardiac and liver siderosis in different populations of patients requiring regular blood transfusions (e.g. thalassaemia major vs. NTDT, thalassaemia major vs. MDS). [ Time Frame: 12 months ] [ Designated as safety issue: No ]Levels of cardiac and liver siderosis will be compared between patient subgroups, according to their primary diagnosis leading to anaemia (e.g. thalassaemia major vs. NTDT, thalassaemia major vs. MDS).
- Relationship between serum ferritin, cardiac and liver iron with cardiac and hepatic events. [ Time Frame: 12 months - retrospective ] [ Designated as safety issue: No ]The relationship between serum ferritin, cardiac and liver iron with cardiac and hepatic events will be assessed all patient subgroups.
- Relationship between BMS and cardiac T2*. [ Time Frame: 1 month ] [ Designated as safety issue: No ]Relationship between BMS and cardiac T2* will be assessed comparing all patient groups.
- Haematologic parameters and transfusion requirement in patients with acquired anaemias with history of receiving chelation therapy. [ Time Frame: 12 months - retrospective ] [ Designated as safety issue: No ]haematologic parameters and transfusion requirement in patients with acquired anaemias with history of receiving chelation therapy will be assessed, in order to evaluate possible impact of chelation on transfusion independence.
- Quality of life and different disease states, levels of iron overload and different chelation regimens. [ Time Frame: 1 month ] [ Designated as safety issue: No ]Quality of life will be assessed comparing different disease states, levels of iron overload and different chelation regimens.
- Adherence of patients according to different chelation regimens. [ Time Frame: 1 month ] [ Designated as safety issue: No ]Adherence of patients according to different chelation regimens (adherence questionnaire will only be recorded for patients receiving chelating agents).
- Treatment decisions based on MRI results. [ Time Frame: 1 month ] [ Designated as safety issue: No ]Treatment decisions will be recorded after the investigator evaluates the MRI results, in order to assess the impact of such diagnostic test on the overall clinical management of patients with iron overload.
| Estimated Enrollment: | 250 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Single arm MRI test
All patients will be subjected to the non-invasive hepatic and cardiac MRI test to measure iron overload.
|
Radiation: Single arm MRI test
All patients will be subjected to the non-invasive hepatic and cardiac MRI test to measure iron overload.
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age ≥ 12 years Confirmed clinical diagnosis of one of the following disease states: 1. Myelodysplastic syndromes, 2. Thalassaemia major, 3.Other anaemias (e.g. NTDT, SCD, Diamond-Blackfan anaemia, aplastic anaemia, myeloproliferative disease) Lifetime history of at least 20 units of red blood cell transfusions AND serum ferritin level > 500 ng/ml; patients with NTDT are not required to have a minimum of 20 units of red blood cell transfusions, but must have serum ferritin level > 300 ng/ml (serum ferritin for all patients must be measured up to 1 month prior to enrollment) Written informed consent obtained prior to any procedure required by this protocol
Exclusion Criteria:
Any condition that does not allow the MRI test to be performed: 1. Cardiac pacemaker, 2. Ferromagnetic metal implants other than those approved as safe for use in MR scanners (Example: some types of aneurysm clips, shrapnel), 3. Obesity (exceeding the equipment limits), 4. Patients who are claustrophobic to MR Women who are pregnant Unwillingness or being unable to give consent
Contacts and Locations| Contact: Novartis Pharmaceuticals | +41613241111 | |
| Contact: Novartis Pharmaceuticals |
| Australia, New South Wales | |
| Novartis Investigative Site | Recruiting |
| Camperdown, New South Wales, Australia, 2050 | |
| Novartis Investigative Site | Recruiting |
| St Leonards, New South Wales, Australia, 2065 | |
| Australia, Queensland | |
| Novartis Investigative Site | Recruiting |
| South Brisbane, Queensland, Australia, 4101 | |
| Novartis Investigative Site | Recruiting |
| Woolloongabba, Queensland, Australia, 4102 | |
| Australia, South Australia | |
| Novartis Investigative Site | Recruiting |
| Adelaide, South Australia, Australia, 5000 | |
| Novartis Investigative Site | Recruiting |
| Bedford Park, South Australia, Australia, 5042 | |
| Australia, Victoria | |
| Novartis Investigative Site | Recruiting |
| East Bentleigh, Victoria, Australia, 3165 | |
| Australia, Western Australia | |
| Novartis Investigative Site | Recruiting |
| Perth, Western Australia, Australia, 6000 | |
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Novartis ( Novartis Pharmaceuticals ) |
| ClinicalTrials.gov Identifier: | NCT01736540 History of Changes |
| Other Study ID Numbers: | CICL670AAU05 |
| Study First Received: | November 26, 2012 |
| Last Updated: | January 30, 2013 |
| Health Authority: | Australia: Human Research Ethics Committee |
Additional relevant MeSH terms:
|
Primary Myelofibrosis Anemia Myelodysplastic Syndromes Preleukemia Siderosis Thalassemia Iron Overload Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases Precancerous Conditions Neoplasms |
Pneumoconiosis Lung Diseases, Interstitial Lung Diseases Respiratory Tract Diseases Lung Injury Occupational Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Iron Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013